AI Generated Image
Eli Lilly plans FDA submission for retatrutide weight-loss drug in 2027
NewsNation • • business
Key Points:
- Eli Lilly plans to seek FDA approval for its next-generation weight-loss drug, retatrutide, in early 2027 following positive results from two late-stage clinical trials.
- Retatrutide showed significant weight loss and improved blood sugar control in adults with obesity and related health conditions, including Type 2 diabetes and cardiovascular disease.
- In clinical trials, patients lost up to 22.6% of their body weight, equivalent to nearly 56 pounds after 80 weeks of treatment.
- Retatrutide is unique in targeting three receptors (GLP-1, GIP, and glucagon), differentiating it from current weight-loss medications that target one or two pathways.
- Lilly aims to submit global regulatory applications for retatrutide as a treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea based on the positive clinical data.
